Logo image of ALSGD.PA

SPINEGUARD SA (ALSGD.PA) Stock Fundamental Analysis

EPA:ALSGD - Euronext Paris - Matif - FR0011464452 - Common Stock - Currency: EUR

0.1058  0 (-2.94%)

Fundamental Rating

1

ALSGD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 59 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALSGD have multiple concerns. ALSGD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALSGD has reported negative net income.
ALSGD had a negative operating cash flow in the past year.
In the past 5 years ALSGD always reported negative net income.
ALSGD had a negative operating cash flow in each of the past 5 years.
ALSGD.PA Yearly Net Income VS EBIT VS OCF VS FCFALSGD.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M -4M

1.2 Ratios

ALSGD has a Return On Assets of -37.45%. This is amonst the worse of the industry: ALSGD underperforms 81.36% of its industry peers.
ALSGD has a worse Return On Equity (-78.95%) than 79.66% of its industry peers.
Industry RankSector Rank
ROA -37.45%
ROE -78.95%
ROIC N/A
ROA(3y)-32.05%
ROA(5y)-28.87%
ROE(3y)-64.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSGD.PA Yearly ROA, ROE, ROICALSGD.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

Looking at the Gross Margin, with a value of 70.80%, ALSGD is in the better half of the industry, outperforming 76.27% of the companies in the same industry.
In the last couple of years the Gross Margin of ALSGD has declined.
ALSGD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5Y-2.09%
ALSGD.PA Yearly Profit, Operating, Gross MarginsALSGD.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

0

2. Health

2.1 Basic Checks

ALSGD does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALSGD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALSGD has been increased compared to 5 years ago.
The debt/assets ratio for ALSGD is higher compared to a year ago.
ALSGD.PA Yearly Shares OutstandingALSGD.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALSGD.PA Yearly Total Debt VS Total AssetsALSGD.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ALSGD has an Altman-Z score of -6.05. This is a bad value and indicates that ALSGD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.05, ALSGD is doing worse than 88.14% of the companies in the same industry.
A Debt/Equity ratio of 0.52 indicates that ALSGD is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.52, ALSGD perfoms like the industry average, outperforming 44.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z -6.05
ROIC/WACCN/A
WACC8%
ALSGD.PA Yearly LT Debt VS Equity VS FCFALSGD.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

2.3 Liquidity

ALSGD has a Current Ratio of 0.97. This is a bad value and indicates that ALSGD is not financially healthy enough and could expect problems in meeting its short term obligations.
ALSGD has a worse Current ratio (0.97) than 76.27% of its industry peers.
ALSGD has a Quick Ratio of 0.97. This is a bad value and indicates that ALSGD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.69, ALSGD is not doing good in the industry: 71.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.97
Quick Ratio 0.69
ALSGD.PA Yearly Current Assets VS Current LiabilitesALSGD.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.95% over the past year.
Looking at the last year, ALSGD shows a small growth in Revenue. The Revenue has grown by 7.77% in the last year.
ALSGD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.41% yearly.
EPS 1Y (TTM)42.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.08%
Revenue 1Y (TTM)7.77%
Revenue growth 3Y1.8%
Revenue growth 5Y-7.41%
Sales Q2Q%5.94%

3.2 Future

ALSGD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.36% yearly.
ALSGD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.09% yearly.
EPS Next Y28.57%
EPS Next 2Y25.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.39%
Revenue Next 2Y17.09%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALSGD.PA Yearly Revenue VS EstimatesALSGD.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
ALSGD.PA Yearly EPS VS EstimatesALSGD.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALSGD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSGD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSGD.PA Price Earnings VS Forward Price EarningsALSGD.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSGD.PA Per share dataALSGD.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 -0.04 0.06

4.3 Compensation for Growth

ALSGD's earnings are expected to grow with 25.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.36%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALSGD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPINEGUARD SA

EPA:ALSGD (6/18/2025, 7:00:00 PM)

0.1058

0 (-2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-15 2025-04-15
Earnings (Next)07-09 2025-07-09
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.58M
Analysts84.44
Price Target0.64 (504.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.42
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.07
BVpS0.06
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.45%
ROE -78.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.8%
FCFM N/A
ROA(3y)-32.05%
ROA(5y)-28.87%
ROE(3y)-64.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5Y-2.09%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.97%
Cap/Sales 7.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.97
Quick Ratio 0.69
Altman-Z -6.05
F-Score4
WACC8%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)170.18%
Cap/Sales(3y)14.39%
Cap/Sales(5y)11.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.08%
EPS Next Y28.57%
EPS Next 2Y25.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.77%
Revenue growth 3Y1.8%
Revenue growth 5Y-7.41%
Sales Q2Q%5.94%
Revenue Next Year10.39%
Revenue Next 2Y17.09%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.99%
OCF growth 3YN/A
OCF growth 5YN/A